Skip to main content


Corporate Profile

Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing a novel class of biological drugs, which we refer to as Ecobiotic microbiome therapeutics, that are designed to restore health by repairing the function of a dysbiotic microbiome. The Company’s lead product candidate, SER-109, is intended to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon, and, if approved by the FDA, could be a first-in-field drug. Using its... More

Recent News
- Four significant microbiome program milestones expected during 2020, including readouts from two late-stage development programs – - Completed public offering of common stock, raising net proceeds of $61M and extending the operating runway into 2021 – - Conference call at 8:00 a.m.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 6, 2019-- Seres Therapeutics, Inc . (Nasdaq: MCRB) today announced the appointment of Stephen Berenson to its Board of Directors. Mr. Berenson is a Managing Partner at Flagship Pioneering and previously spent his career as an investment banker at J.P.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 1, 2019-- Seres Therapeutics, Inc . (Nasdaq: MCRB) today announced that it will present at the Canaccord Genuity 39 th Annual Growth Conference in Boston, MA on Wednesday, August 7 at 8:00 a.m. ET . A live audio webcast of the presentation will be available
There are currently no events to display.
Stock Quote

E-mail Alerts

Sign up to receive e-mail alerts whenever Seres Therapeutics, Inc. posts new information to the site. Just enter your e-mail address and click Submit.

Request Information

Obtain investor relations information by contacting us.


Back to top